Login
$ENTX
$3.02 +$0.00 (0.0%) After hours

$ENTX SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G
06 Nov 2026 10-Q
06 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026

30 Oct 2026 SCHEDULE 13G
27 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN)

14 Oct 2026 Proxy statement: special meeting on November 24, 2026
06 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies

23 Sep 2026 PRE 14A
28 Aug 2026 EFFECT
28 Aug 2026 424B3
21 Aug 2026 S-3
21 Aug 2026 Form 3: Camisasca Riccardo Paolo, Chief Medical Officer

No securities owned

18 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

12 Aug 2026 D
07 Aug 2026 Form 4: Rubin Steven D, Director

Received 19,117 shares as a grant or award · Granted 76,773 Stock Option (right to buy)

07 Aug 2026 Form 4: Malca Yonatan, Director

Received 22,815 shares as a grant or award

07 Aug 2026 Form 4: Taitel Haya, Director

Received 20,790 shares as a grant or award

07 Aug 2026 Form 4: Ellis Sean, Director

Received 20,034 shares as a grant or award · Granted 40,000 Stock Option (right to buy)

07 Aug 2026 Form 4: Yaacov-Garbeli Dana, Chief Financial Officer

Granted 140,000 Stock Option (right to buy)

07 Aug 2026 Form 4: Galitzer Hillel, Chief Operating Officer

Granted 200,000 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support